Characteristics of HIV-infected adults and general US population adults, MMP and NHANES 2009–2010
| HIV-infected adults* | General population adults* | |||
|---|---|---|---|---|
| Sample n | Weighted % (95% CI) | Sample n | Weighted % (95% CI) | |
| Total | 8610 | – | 5604 | – |
| Sex at birth | ||||
| Male | 6349 | 73.6 (70.3 to 76.7) | 2745 | 49.3 (48.1 to 50.6) |
| Female | 2261 | 26.4 (23.3 to 29.7) | 2859 | 50.7 (49.4 to 51.9) |
| Race/ethnicity | ||||
| White (non-Hispanic) | 2869 | 34.6 (27.6 to 42.3) | 2584 | 67.3 (59.8 to 74.0) |
| Black (non-Hispanic) | 3512 | 41.3 (32.4 to 50.8) | 1051 | 11.7 (10.0 to 13.7) |
| Hispanic or Latino | 1827 | 19.3 (14.2 to 25.7) | 1656 | 14.0 (8.8 to 21.3) |
| Other | 402 | 4.9 (3.9 to 6.0) | 313 | 7.1 (5.1 to 9.9) |
| Age in years | ||||
| 20–44 | 3412 | 40.1 (38.7 to 41.5) | 2518 | 48.6 (46.2 to 51.1) |
| 45–60 | 4366 | 50.3 (48.9 to 51.6) | 1473 | 29.8 (28.5 to 31.1) |
| ≥60 | 832 | 9.6 (8.8 to 10.6) | 1613 | 21.6 (20.1 to 23.2) |
| Education | ||||
| Less than high school | 1937 | 21.5 (19.1 to 24.1) | 1570 | 18.4 (16.5 to 20.5) |
| High school or equivalent | 2314 | 26.3 (24.1 to 28.7) | 1289 | 22.9 (20.7 to 25.2) |
| More than high school | 4356 | 52.2 (47.7 to 56.6) | 2722 | 58.7 (55.7 to 61.7) |
| Living at or below poverty line† | ||||
| Yes | 3790 | 43.5 (39.6 to 47.5) | 713 | 8.5 (7.0 to 10.3) |
| No | 4565 | 56.5 (52.5 to 60.4) | 4608 | 91.5 (89.7 to 93.0) |
| Obese (BMI ≥30 kg/m2) | ||||
| Yes | 2071 | 25.5 (23.9 to 27.2) | 2073 | 36.0 (34.0 to 38.2) |
| No | 6208 | 74.5 (72.8 to 76.2) | 3291 | 64.0 (61.9 to 66.0) |
| Hepatitis C virus‡ | ||||
| Positive | 1556 | 20.6 (18.7 to 22.7) | 106 | 1.7 (1.2 to 2.4) |
| Negative | 5590 | 79.4 (77.3 to 81.3) | 5190 | 98.3 (97.6 to 98.8) |
| Time since HIV diagnosis | ||||
| Less than 5 years | 1866 | 22.4 (20.7 to 24.1) | – | – |
| 5–9 years | 1932 | 22.6 (21.6 to 23.6) | – | – |
| 10 or more years | 4806 | 55.0 (52.8 to 57.3) | – | – |
| AIDS/nadir CD4 count in cells/mm3 | ||||
| AIDS or nadir CD4 0-199 | 5952 | 68.5 (67.2 to 69.7) | – | – |
| No AIDS and nadir CD4 200–500 | 2098 | 24.8 (23.4 to 26.2) | – | – |
| No AIDS and nadir CD4 >500 | 540 | 6.8 (6.0 to 7.6) | – | – |
| Geometric mean CD4 past 12 months | ||||
| 0–199 cells/mm3 | 1118 | 13.0 (12.1 to 13.9) | – | – |
| 200–349 cells/mm3 | 1486 | 17.9 (16.9 to 19.1) | – | – |
| 350–499 cells/mm3 | 1949 | 23.6 (22.6 to 24.7) | – | – |
| ≥500 cells/mm3 | 3739 | 45.5 (44.0 to 47.0) | – | – |
| Prescribed ART | ||||
| Yes | 7751 | 90.0 (89.2 to 90.7) | – | – |
| No | 828 | 10.1 (9.3 to 10.8) | – | – |
| Most recent viral load undetectable or <200 copies/mL | ||||
| Yes | 6287 | 73.0 (71.0 to 75.0) | – | – |
| No | 2323 | 27.0 (25.1 to 29.1) | – | – |
*Includes adults ≥20 years of age and excludes pregnant women.
†Calculated using the ratio of annual household income to number of people in the household.
‡A total of n=7146 and n=5295 were screened for hepatitis C (HCV) in MMP and NHANES, respectively. HCV positivity was defined as having a documented positive anti-HCV enzyme immunoassay or strip immunoblot assay RIBA, HCV genotype, or HCV RNA through reverse transcriptase–PCR (RT–PCR).
ART, antiretroviral therapy; BMI, body mass index; MMP, Medical Monitoring Project; NHANES, National Health and Nutrition Examination Survey.